Open AccessDrug review: Carfilzomib
Author(s) -
Prasanth Ganesan
Publication year - 2019
Publication title -
indian journal of medical and paediatric oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 22
eISSN - 0975-2129
pISSN - 0971-5851
DOI - 10.4103/ijmpo.ijmpo_67_19
Subject(s) - carfilzomib , medicine , proteasome inhibitor , drug , multiple myeloma , refractory (planetary science) , pharmacology , clinical trial , intensive care medicine , oncology , physics , astrobiology
Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.